Musquer M, Jouand N, Pere M, Lamer J, Bezieau S, Matysiak T
Front Oncol. 2021; 11:684478.
PMID: 34211852
PMC: 8239306.
DOI: 10.3389/fonc.2021.684478.
Epistolio S, Cefali M, Spina P, Molinari F, Movilia A, Cergnul M
Oncotarget. 2021; 12(11):1046-1056.
PMID: 34084279
PMC: 8169066.
DOI: 10.18632/oncotarget.27965.
Zhu X, Meng X, Xiang W, Dai W, Bai Q, Sheng W
Int J Clin Exp Pathol. 2020; 11(5):2839-2845.
PMID: 31938404
PMC: 6958270.
Jin Z, Hubbard J
Curr Oncol. 2019; 26(Suppl 1):S33-S42.
PMID: 31819708
PMC: 6878937.
DOI: 10.3747/co.26.5589.
Hsu H, Liu Y, Wang C, Chou W, Hsu Y, Chiang J
Cancer Med. 2019; 8(7):3437-3446.
PMID: 31090176
PMC: 6601597.
DOI: 10.1002/cam4.2235.
The tumour microenvironment and immune milieu of cholangiocarcinoma.
Fabris L, Perugorria M, Mertens J, Bjorkstrom N, Cramer T, Lleo A
Liver Int. 2019; 39 Suppl 1:63-78.
PMID: 30907492
PMC: 10878127.
DOI: 10.1111/liv.14098.
MicroRNAs as Mediators of Resistance Mechanisms to Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumours.
Ghidini M, Hahne J, Frizziero M, Tomasello G, Trevisani F, Lampis A
Target Oncol. 2018; 13(4):423-436.
PMID: 30006826
DOI: 10.1007/s11523-018-0580-3.
Non-Coding RNAs and Resistance to Anticancer Drugs in Gastrointestinal Tumors.
Hahne J, Valeri N
Front Oncol. 2018; 8:226.
PMID: 29967761
PMC: 6015885.
DOI: 10.3389/fonc.2018.00226.
β-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models.
Ganesh S, Shui X, Craig K, Koser M, Chopda G, Cyr W
Mol Cancer Ther. 2017; 17(2):544-553.
PMID: 29282298
PMC: 5805618.
DOI: 10.1158/1535-7163.MCT-17-0605.
Liposomal Cu-PET Imaging of Anti-VEGF Drug Effects on Liposomal Delivery to Colon Cancer Xenografts.
Blocker S, Douglas K, Polin L, Lee H, Hendriks B, Lalo E
Theranostics. 2017; 7(17):4229-4239.
PMID: 29158822
PMC: 5695009.
DOI: 10.7150/thno.21688.
Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma.
Lievre A, Ouine B, Canet J, Cartier A, Amar Y, Cacheux W
Br J Cancer. 2017; 117(12):1819-1827.
PMID: 29024937
PMC: 5729470.
DOI: 10.1038/bjc.2017.353.
Primary and acquired resistance to biologic therapies in gastrointestinal cancers.
Lubner S, Uboha N, Deming D
J Gastrointest Oncol. 2017; 8(3):499-512.
PMID: 28736637
PMC: 5506279.
DOI: 10.21037/jgo.2017.01.16.
Quality of life during first-line FOLFOX4±panitumumab in wild-type metastatic colorectal carcinoma: results from a randomised controlled trial.
Siena S, Tabernero J, Bodoky G, Cunningham D, Rivera F, Ruff P
ESMO Open. 2016; 1(2):e000041.
PMID: 27843597
PMC: 5070244.
DOI: 10.1136/esmoopen-2016-000041.
Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer.
Graham D, Coyle V, Kennedy R, Wilson R
Curr Colorectal Cancer Rep. 2016; 12:141-150.
PMID: 27340376
PMC: 4879165.
DOI: 10.1007/s11888-016-0312-y.
Skin toxicity and quality of life during treatment with panitumumab for RAS wild-type metastatic colorectal carcinoma: results from three randomised clinical trials.
Koukakis R, Gatta F, Hechmati G, Siena S
Qual Life Res. 2016; 25(10):2645-2656.
PMID: 27083443
PMC: 5010834.
DOI: 10.1007/s11136-016-1288-4.
Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?.
Derangere V, Fumet J, Boidot R, Bengrine L, Limagne E, Chevriaux A
Oncotarget. 2016; 7(8):9309-21.
PMID: 26824184
PMC: 4891042.
DOI: 10.18632/oncotarget.7008.
KRAS mutation in lung metastases from colorectal cancer: prognostic implications.
Ghidini M, Personeni N, Bozzarelli S, Baretti M, Basso G, Bianchi P
Cancer Med. 2015; 5(2):256-64.
PMID: 26715198
PMC: 4735767.
DOI: 10.1002/cam4.592.
Cost-effectiveness of RAS screening before monoclonal antibodies therapy in metastatic colorectal cancer based on FIRE3 Study.
Wen F, Yang Y, Zhang P, Zhang J, Zhou J, Tang R
Cancer Biol Ther. 2015; 16(11):1577-84.
PMID: 26418570
PMC: 4846122.
DOI: 10.1080/15384047.2015.1095398.
KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET-expressing tumor cells.
Leiser D, Medova M, Mikami K, Nisa L, Stroka D, Blaukat A
Mol Oncol. 2015; 9(7):1434-46.
PMID: 25933688
PMC: 5528816.
DOI: 10.1016/j.molonc.2015.04.001.
Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity.
Catenacci D
Mol Oncol. 2015; 9(5):967-96.
PMID: 25557400
PMC: 4402102.
DOI: 10.1016/j.molonc.2014.09.011.
